In-person & virtual event - Lacutamab: a Phase 3-ready asset
Click here to register & attend
Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma
More about our lead asset
IPH4502, our Antibody Drug Conjugate targeting Nectin-4
More about this asset
Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca
More about this asset
Collaborating with a strong network to advance our pipeline
Discover our partnering opportunities